JHD205,一种新的abemaciclib衍生物,通过CDK4/6对乳腺癌产生抗瘤作用
Jing Ji1, Jingting Qin1, Xiaoshuo Wang1
1Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, China.
一种名为JHD205的新化合物在治疗三阴性乳腺癌 (TNBC) 中表现有前途. 这种选择性CDK4/6抑制剂有效地抑制瘤生长,并诱导癌细胞死亡.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 三阴性乳腺癌 (TNBC) 是一种侵略性的亚型,需要新的治疗方法.
- 目前TNBC的治疗选择有限,突出了针对性分子疗法的需要.
研究的目的:
- 调查选择性循环素依赖性激酶4/6 (CDK4/6) 抑制剂在TNBC治疗中的疗效.
- 评估一种新型化合物,JHD205,作为TNBC的潜在治疗剂.
主要方法:
- 合成的JHD205,一个衍生品的Abemaciclib.
- 在临床前模型中评估JHD205对TNBC细胞增殖和生存的影响.
- 西部斑点分析以确定JHD205作用的分子机制.
主要成果:
- 在乳腺癌异种移植模型中,JHD205与Abemaciclib相比,表现出优异的瘤生长抑制.
- JHD205剂量依赖地降解了CDK4和CDK6,影响了细胞循环的关键调节器 (p-Rb,Rb,E2F1).
- JHD205诱导了细胞亡和DNA损伤,同时抑制了DNA修复途径 (升调Caspase3和p-H2AX).
结论:
- JHD205对TNBC具有显著的抗癌活性.
- 这些发现支持JHD205作为乳腺癌治疗的有希望的候选人.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
相关概念视频
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Anaphase Promoting Complex
Mitogens and the Cell Cycle
